文献速递白血病淋巴瘤

慢性淋巴细胞白血病患者新冠疫苗接种期间暂停布鲁顿酪氨酸激酶抑制剂3周对比持续用药的随机开放标签优效性试验(IMPROVE试验)

A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial.
PubMed 文献 · Lancet Haematol · 2025-01-01

IMPROVE试验在11家英国医院纳入99例正在服用BTKi至少12个月的慢性淋巴细胞白血病患者,随机分为暂停BTKi 3周组(n=50)或继续用药组(n=49),比较新冠疫苗加强接种后3周的抗刺突蛋白受体结合域抗体滴度。继续组几何平均滴度为218.8 U/mL(SD 122.9),暂停组为153.4 U/mL(SD 103.2),几何平均比值为1.104(95% CI 0.565-2.158,p=0.77),两组无显著差异。作者认为围绕疫苗接种暂停BTKi对免疫无益,不应在临床实践中推荐。

要点

  • 暂停BTKi 3周组接种后3周抗RBD抗体几何平均滴度为153.4 U/mL(SD 103.2),继续组为218.8 U/mL(SD 122.9)。
  • 两组几何平均比值为1.104(95% CI 0.565-2.158,p=0.77),无统计学显著差异。
  • 作者认为围绕疫苗接种暂停BTKi对免疫无益,不应在临床实践中推荐。

核心结论

  • 尽管研究把握度略有不足,结果提示围绕疫苗接种暂停BTKi对免疫无益,不应在临床实践中推荐。

研究设计与样本

  • 开放标签、双臂、平行组、随机优效性试验,在11家英国医院的二级诊疗血液科诊所开展。
  • 纳入年龄18岁及以上、确诊慢性淋巴细胞白血病且正在接受BTKi治疗(一线或复发 setting)至少12个月的患者。
  • 共99例参与者按1:1中央计算机随机(按BTKi治疗线分层)分配至暂停BTKi 3周组(n=50)或继续用药组(n=49),随访12周。
  • 暂停组从新冠疫苗加强接种日期前6天开始暂停BTKi 3周;参与者与临床工作人员未设盲,实验室工作人员设盲。
  • 接种疫苗为原始BA.1或原始BA.4/5二价mRNA疫苗(50 μg mRNA-1273或30 μg BNT162b2)肌肉注射,或5 μg蛋白基Vidprevtyn Beta(Sanofi Pasteur,法国里昂),按国家疫苗接种规划日程接种。

主要发现

  • 2022年10月10日至2023年6月8日期间,99例参与者(71例[72%]男性、28例[28%]女性,89例[90%]为白人)被随机分配至暂停组(n=50[51%])或继续组(n=49[49%]),随访12周。
  • 接种后3周,继续组抗刺突蛋白受体结合域特异性抗体几何平均滴度为218.8 U/mL(SD 122.9),暂停组为153.4 U/mL(SD 103.2)。
  • 采用混合效应模型,几何平均比值为1.104(95% CI 0.565-2.158,p=0.77)。
  • 12周随访期间唯一严重不良事件为暂停组1例参与者在随机分组后2个月死于COVID-19感染。

关键数值与推荐

  • 主要结局抗刺突蛋白受体结合域特异性抗体滴度:继续组几何平均滴度218.8 U/mL(SD 122.9)vs 暂停组153.4 U/mL(SD 103.2)。
  • 几何平均比值1.104(95% CI 0.565-2.158,p=0.77),差异无统计学显著性。

临床怎么用

  • 作者认为围绕疫苗接种暂停BTKi对免疫无益,不应在临床实践中推荐。

局限性

  • 研究把握度略有不足(slightly underpowered)。
  • 研究为开放标签设计,参与者和临床工作人员未设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic lymphocytic leukaemia is the commonest leukaemia and is associated with profound immunosuppression. Bruton tyrosine kinase inhibitors (BTKi) have revolutionised chronic lymphocytic leukaemia management; however, therapy impairs vaccine-induced immunity. We evaluated whether a 3-week pause of BTKi treatment improved spike protein receptor binding domain (RBD) immunity to SARS-CoV-2 booster vaccination while maintaining disease control. METHODS: We performed an open-label, two-arm, parallel-group, randomised trial in secondary-care haematology clinics in 11 UK hospitals. Participants aged 18 years or older, diagnosed with chronic lymphocytic leukaemia, and currently taking BTKi therapy (frontline or relapsed setting) for at least 12 months were eligible. Participants were randomly allocated (1:1, by a centralised computer randomisation program, stratified by BTKi therapy line) to pause BTKi for 3 weeks, starting 6 days before their SARS-CoV-2 vaccination booster date, or to continue therapy as usual. Neither participants nor clinical staff were blinded but laboratory staff were. Intramuscular injection of either original BA.1 or original BA.4/5 bivalent mRNA vaccine (50 μg mRNA-1273 or 30 μg BNT162b2), or 5 μg protein-based Vidprevtyn Beta (Sanofi Pasteur, Lyon, France) were received according to the national vaccination programme schedule. The primary outcome measure was anti-spike-RBD-specific antibody titre 3 weeks after vaccination and analysis performed by intention to treat (as randomly allocated, irrespective of compliance) following trial completion. This trial is registered with ISRCTN, 14197181, and has been completed. FINDINGS: Between Oct 10, 2022, and June 8, 2023, 99 individuals (71 [72%] male and 28 [28%] female, with 89 [90%] of White ethnicity) were randomly allocated to groups pausing (n=50 [51%]) or continuing (n=49 [49%]) their BTKi therapy, and followed up for 12 weeks. At 3 weeks after vaccination, the geometric mean anti-spike-RBD-specific antibody titre was 218·8 U/mL (SD 122·9) in the continue group and 153·4 U/mL (103·2) in the pause group, with geometric mean ratio 1·104 (95% CI 0·565-2·158, p=0·77) using a mixed-effects model. The only serious adverse event during the 12-week follow-up was the death of one participant in the pause group due to COVID-19 infection 2 months after randomisation. INTERPRETATION: Although the study was slightly underpowered, the results suggest that pausing BTKi around the time of vaccination is not beneficial for immunity and should not be recommended in clinical practice. FUNDING: National Institute for Health and Care Research.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Cook JA, Patten PEM, Peckham N, et al. A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial. Lancet Haematol. 2025. PMID: 40175001. doi:10.1016/S2352-3026(25)00008-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。